CELLO Health BioConsulting Webinar with Real Endpoints: In this senior executive webinar, we’ll give a boardroom presentation, and take your questions, on cancer’s unique payer situation and its stability — or instability. Our focus: how the informed biotech executive team manages early (and late) clinical and commercial development to ensure success not just with the FDA but in what may be a very different and less favorable reimbursement environment

Watch the replay of Real Endpoint’s Jane Barlow – joined by Congressman Scott Peters – speaking to the challenges of seeking reimbursement for cell and gene therapy during a time of upheaval.

Value-based pharma contracts have been rare in oncology relative to other therapeutic categories — and for a variety of good and bad reasons. But in the hyper-competitive future, risk-sharing will become a necessary component in every oncology company’s strategic toolkit. In five separate sessions at the value-based cancer summit in NY Oct 16-18, Real Endpoints CEO Jeff Berkowitz and Chairman Roger Longman will help lay out the challenges and the unexploited opportunities in oncology VBAs

Biotech’s CEOs at the annual Laguna meeting next week will be talking — as are their investors — about how to pay for innovation, particularly as the industry runs from major chronic disease to narrow orphan indications where pricing has been relatively protected. Real Endpoints’ CEO Jeff Berkowitz will be on a panel defining the increasing challenges of this approach, particularly given how competitive even the narrowest orphan conditions have become, and how companies must adapt to meet them.

Real Endpoints Founder, Roger Longman, is looking forward to leading a robust discussion focused on solutions to creating access to cell and gene therapies — solutions that work for both payers and biopharma.

Taking place on the first day of ASCO, the 5th Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.